Insider Selling: Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells $16,872.49 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Peter Greenleaf sold 797 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $21.17, for a total value of $16,872.49. Following the transaction, the director directly owned 23,087 shares of the company’s stock, valued at $488,751.79. The trade was a 3.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Stock Performance

NYSEAMERICAN PTHS opened at $20.50 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.98 and a quick ratio of 1.31. The stock’s 50 day simple moving average is $24.40 and its 200-day simple moving average is $25.18. The company has a market cap of $78.52 million, a PE ratio of -0.94 and a beta of 3.07. Pelthos Therapeutics Inc. has a 1-year low of $18.19 and a 1-year high of $37.50.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. The firm had revenue of $15.60 million for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. As a group, equities research analysts anticipate that Pelthos Therapeutics Inc. will post -15.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Pelthos Therapeutics

A hedge fund recently raised its stake in Pelthos Therapeutics stock. Knott David M Jr lifted its stake in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 9.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 21,073 shares of the company’s stock after acquiring an additional 1,792 shares during the quarter. Knott David M Jr owned 0.63% of Pelthos Therapeutics worth $443,000 at the end of the most recent reporting period. Institutional investors own 77.96% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Oppenheimer decreased their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a research note on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.40.

Pelthos Therapeutics Company Profile

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited.